Hoarseness: Drugs That Cause or Treat It

What Is Hoarseness and Why Does It Matter?

Hoarseness, formally called dysphonia, is any abnormal change in voice quality, pitch, or loudness caused by altered vibration of the vocal folds. It affects an estimated 1 in 3 adults at some point in their lives and accounts for roughly 12 million outpatient visits per year in the United States. Drug-induced dysphonia is underreported because both patients and prescribers rarely connect a voice change to a medication started weeks earlier.

The Vocal Fold Mechanism

The vocal folds are paired mucosa-covered muscles stretched across the larynx. Normal voice production requires precise adduction, mucosal wave propagation, and adequate subglottic pressure. Any drug that changes mucosal hydration, neuromuscular control, tissue architecture, or local immune defense can disrupt this process and produce perceptible hoarseness.

Scope of the Problem

A 2018 systematic review in the Journal of Voice identified more than 50 drug classes with at least one published case report or controlled trial documenting dysphonia as an adverse effect. The same review noted that drug-induced hoarseness is the second most common reversible cause of dysphonia after acute viral laryngitis, yet it is frequently misattributed to reflux or vocal overuse.

Inhaled Corticosteroids: The Most Documented Drug Cause

Inhaled corticosteroids (ICS) such as fluticasone propionate, budesonide, beclomethasone, and ciclesonide are the best-studied drug cause of hoarseness. Prevalence estimates range from 5% to 58% depending on the device type, dose, and how dysphonia is measured. One controlled study (N=147) found objective voice changes in 34% of asthma patients using high-dose fluticasone compared with 6% on placebo (P<0.001).

Why ICS Causes Hoarseness

Two mechanisms account for most cases. First, deposited steroid particles cause a local myopathy of the posterior cricoarytenoid muscle, the only abductor of the vocal folds, leading to vocal fold bowing and a rough, breathy voice quality. Second, oropharyngeal candidiasis from immune suppression inflames the supraglottic structures. The myopathic mechanism is dose-dependent and does not always resolve when the drug is stopped.

Reducing ICS-Related Hoarseness

A 2013 Cochrane review of 12 randomized controlled trials confirmed that spacer devices combined with mouth rinsing after each dose significantly reduce oropharyngeal drug deposition compared with pressurized metered-dose inhalers used alone. Ciclesonide, a pro-drug activated in the lungs rather than the oropharynx, carries a lower risk of local adverse effects than equipotent doses of fluticasone. Switching device type or reducing to the minimum effective dose resolves dysphonia in most patients within four to six weeks.

ACE Inhibitors and the Cough-Dysphonia Connection

ACE inhibitors, including lisinopril, enalapril, and ramipril, are prescribed to an estimated 35 million Americans for hypertension and heart failure. Their most recognized laryngeal side effect is the dry cough that occurs in 5 to 20% of users due to bradykinin and substance P accumulation in the airway mucosa. Chronic coughing mechanically traumatizes the vocal folds, producing contact granulomas, mucosal edema, and secondary dysphonia.

Switching to an ARB

Angiotensin receptor blockers (ARBs) such as losartan and valsartan do not inhibit bradykinin breakdown and carry a cough rate of roughly 1 to 3%, approximately 10-fold lower than ACE inhibitors. The ONTARGET trial (N=25,620) demonstrated non-inferior cardiovascular outcomes for telmisartan versus ramipril, supporting ARB substitution when ACE inhibitor-related laryngeal symptoms are problematic. Resolution of hoarseness typically occurs within two to four weeks of the switch.

Antihistamines, Anticholinergics, and Mucosal Drying

First-generation antihistamines (diphenhydramine, chlorpheniramine) and anticholinergic drugs (oxybutynin, solifenacin, tiotropium) reduce glandular secretions throughout the body. The vocal fold epithelium depends on a thin mucus film for lubrication; drying this layer raises vocal fold viscosity and increases the phonation threshold pressure required to initiate vibration. Research by Titze and colleagues showed that a 10% increase in vocal fold surface viscosity raises phonation threshold pressure by a clinically perceptible amount, translating into vocal fatigue and roughness within hours of drug administration.

Clinical Relevance for Singers and Professional Voice Users

Professional voice users are disproportionately affected. A single dose of 25 mg diphenhydramine has been shown to produce measurable aerodynamic changes in trained singers even without subjective complaint. Second-generation antihistamines (cetirizine, fexofenadine, loratadine) carry significantly less drying effect and are the preferred choice when antihistamine therapy cannot be avoided. Adequate hydration, targeting at least 2 liters of water per day, partially counteracts the viscosity increase.

Antipsychotics and Dopaminergic Drugs

Antipsychotic medications targeting the dopamine D2 receptor, including haloperidol, risperidone, and older typical antipsychotics, can cause laryngeal dystonia or tardive dysphonia, a movement disorder specifically affecting the larynx. A case series published in Movement Disorders described 16 patients with tardive dysphonia, 14 of whom had received a dopamine-blocking agent for at least six months. The voice quality in tardive dysphonia is characteristically strained and strangled, often confused with adductor spasmodic dysphonia.

Distinguishing Tardive Dysphonia from Spasmodic Dysphonia

The distinction matters clinically because tardive dysphonia may partially or fully resolve after the offending drug is tapered and discontinued, whereas idiopathic spasmodic dysphonia does not. Botulinum toxin type A (onabotulinumtoxinA, 1.25 to 2.5 units per vocal fold) is FDA-approved for adductor spasmodic dysphonia and has been used off-label with benefit in tardive dysphonia when drug discontinuation alone is insufficient.

Hormonal Drugs and Voice Change

Sex hormones exert direct effects on laryngeal tissue. The larynx expresses androgen receptors, and testosterone-driven growth during male puberty permanently enlarges the larynx and lowers fundamental frequency. The same process can occur in adult women exposed to exogenous androgens.

Testosterone Therapy in Women

Women receiving testosterone replacement for hypoactive sexual desire disorder or as part of gender-affirming care may experience permanent lowering of the speaking fundamental frequency (SFF). A prospective study of 12 transgender men documented a mean SFF decrease from 196 Hz to 124 Hz after 12 months of testosterone therapy. The change is largely irreversible after six to twelve weeks of exposure. Women using testosterone formulations for libido should receive pre-treatment voice assessment and counseling about this risk.

Danazol and Progestogens

Danazol, a synthetic androgen used historically for endometriosis and hereditary angioedema, carries a well-documented risk of permanent virilization including voice lowering. The FDA label for danazol includes a boxed warning noting that androgenic effects, including voice changes, may not be reversible. Progesterone-dominant contraceptive pills carry a much smaller but measurable androgenic effect on the larynx at high doses.

Thyroid Hormones

Both hypothyroidism and hyperthyroidism alter vocal fold tissue. Myxedematous infiltration of the vocal folds in hypothyroidism produces a deep, rough voice that improves with levothyroxine replacement. Over-replacement with levothyroxine, targeting a TSH below 0.1 mIU/L in thyroid cancer suppression protocols, can cause vocal tremor resembling essential tremor of the larynx.

Bisphosphonates and Esophageal Irritation

Oral bisphosphonates, including alendronate and risedronate, require upright posture for 30 to 60 minutes after ingestion to prevent esophageal erosion. Esophageal reflux of the pill or stomach acid in patients who do not comply with these instructions can reach the posterior larynx, causing chemical laryngitis and hoarseness. A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) identified 41 reports of bisphosphonate-related esophageal and laryngeal injury over a five-year surveillance period.

Chemotherapy Agents and Radiation Sensitizers

Several cytotoxic and targeted therapies produce hoarseness through distinct pathways. Docetaxel and vincristine can cause peripheral neuropathy affecting the recurrent laryngeal nerve, producing unilateral vocal fold paralysis and a breathy, weak voice. A retrospective cohort study (N=88) found new-onset dysphonia in 14% of patients receiving docetaxel-based regimens, with laryngoscopy confirming vocal fold hypomobility in half of those cases.

Checkpoint inhibitor immunotherapy, including pembrolizumab and nivolumab, can trigger immune-mediated laryngitis as part of a broader immune-related adverse event (irAE) profile. Onset is typically six to twelve weeks after initiation. Oral corticosteroids at 1 mg/kg/day prednisone-equivalent, the standard irAE management approach per ASCO guidelines (2021), usually resolve laryngeal inflammation within two to three weeks.

Drugs Used to Treat Hoarseness

Not all drug-voice interactions are harmful. Several medication classes are used therapeutically for dysphonia.

Proton Pump Inhibitors for Laryngopharyngeal Reflux

Laryngopharyngeal reflux (LPR) is one of the most common causes of chronic hoarseness. Gastric acid and pepsin reaching the posterior larynx cause erythema, edema, and vocal fold granulomas. Proton pump inhibitors (PPIs) such as omeprazole 20 to 40 mg twice daily for at least eight weeks are the standard pharmacologic approach. A randomized trial published in JAMA (N=145) found that 40 mg esomeprazole twice daily improved laryngoscopic findings and voice-related quality of life versus placebo over twelve weeks, though symptom response required the full treatment duration.

Antifungals for Candida Laryngitis

Oropharyngeal and laryngeal candidiasis from ICS use or immunosuppression responds to oral fluconazole 150 mg as a single dose or 100 mg daily for seven days. Nystatin suspension is less effective for laryngeal candidiasis because topical contact with the vocal folds is unreliable; systemic azoles are preferred. Confirmation by laryngoscopy showing white plaques on the vocal folds avoids empiric treatment errors.

Botulinum Toxin for Spasmodic Dysphonia

OnabotulinumtoxinA injected percutaneously into the thyroarytenoid muscle under electromyographic guidance is the most effective treatment for adductor spasmodic dysphonia, with response rates of 80 to 90% in published series. The effect lasts 10 to 18 weeks, requiring periodic re-injection. Typical starting doses range from 1.25 to 2.5 units per vocal fold. Voice quality improves within two to five days of injection and may be transiently breathy for the first one to two weeks.

Corticosteroids for Acute Laryngitis

Short-course systemic corticosteroids (dexamethasone 0.6 mg/kg intramuscularly or oral prednisone 40 to 60 mg for five days) can reduce vocal fold edema in acute infectious laryngitis or allergic laryngitis when rapid voice restoration is needed (for example, in professional voice users before performance). A Cochrane review of corticosteroids for croup confirmed the anti-edema mechanism, though direct laryngitis RCT data remain limited.

Diagnosis: How Hoarseness Is Evaluated

The AAO-HNS 2018 Clinical Practice Guideline on Hoarseness (Dysphonia) states: "Clinicians should perform laryngoscopy, or refer to a clinician who can perform laryngoscopy, when hoarseness fails to resolve by a maximum of three months after onset, or when a serious underlying cause is suspected."

History and Medication Review

A full medication reconciliation is the single highest-yield step in evaluating new hoarseness. The clinician should ask about ICS devices and technique, ACE inhibitor use, androgen or hormone therapy, recent chemotherapy, and any drug started within the six weeks before voice change onset. Timing of symptom onset relative to drug initiation often reveals the culprit.

Laryngoscopy Findings by Drug Class

| Drug Class | Typical Laryngoscopic Finding | |---|---| | Inhaled corticosteroids | Vocal fold bowing, erythema, candidal plaques | | ACE inhibitor-related cough | Contact granuloma, vocal fold edema | | Anticholinergics | Dry, thickened mucus; normal fold architecture | | Antipsychotics (tardive) | Irregular adductory spasms on phonation | | Testosterone therapy | Enlarged, thickened vocal folds; reduced SFF | | Checkpoint inhibitors | Diffuse erythema, subglottic edema |

When to Refer Urgently

Hoarseness combined with any of the following findings requires same-day or next-day laryngoscopy and possible imaging.

• Stridor (high-pitched noise on inspiration) suggesting airway compromise
• Dysphagia or odynophagia alongside dysphonia, raising concern for hypopharyngeal malignancy
• Unilateral vocal fold paralysis without an identified cause
• Hoarseness in a current or former smoker persisting beyond three weeks
• Neck mass palpable on examination
• Hemoptysis

The National Comprehensive Cancer Network (NCCN) guidelines for head and neck cancers note that the median time from symptom onset to diagnosis of laryngeal squamous cell carcinoma exceeds six months, and diagnostic delay of more than ninety days is independently associated with a higher stage at presentation.

Practical Drug Management Framework

Three questions guide clinical decision-making when a drug is suspected as the cause of hoarseness.

Question 1: Is the drug necessary? If the offending agent can be stopped safely, do so and reassess voice at four weeks.

Question 2: Can the drug be substituted? For ICS-related hoarseness, trial ciclesonide or add a spacer before abandoning ICS therapy. For ACE inhibitor cough, substitute an ARB. For anticholinergics, choose a second-generation antihistamine or reduce the dose.

Question 3: Can the delivery or technique be optimized? Patients using ICS should rinse their mouths and gargle with water for 30 seconds after every dose. A valved holding chamber (spacer) reduces oropharyngeal deposition by 50 to 80% compared with an unspacered MDI.

If hoarseness persists beyond four to six weeks despite the above measures, laryngoscopy is indicated regardless of the suspected drug cause.